Find a study
Browse recruiting studies near you — free to check, always your choice.
115 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Depression
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Testing lumateperone added to usual care for major depressive disorder
📍 University of Alabama at Birmingham · Huntsville, AL · +24 more US sites · Get directions →
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
- Depression
The Role of mGluR5 in CBT-I
Testing how a brain receptor may affect CBT-I for insomnia in people with depression
📍 Stony Brook University: Dept of Psychiatry · Stony Brook, NY · Get directions →
This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.
- Depression
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Testing azetukalner compared with a placebo for adults with major depression
📍 Harmonex Neuroscience Research · Dothan, AL · +33 more US sites · Get directions →
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
- Kidney disease
Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis
Testing amino acid supplements during hemodialysis for fatigue and thinking in end-stage kidney
📍 The University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →
The study will test and compare the efficacy of a single essential amino acid valine with a combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.
- Depression
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
Testing brain scan and EEG measures to predict response to depression treatment
📍 Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 · Austin, TX · Get directions →
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.
- Kidney disease
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Testing whether empagliflozin is safe and helps children with chronic kidney disease
📍 University of Alabama at Birmingham · Birmingham, AL · +29 more US sites · Get directions →
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD.
- Depression
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Testing azetukalner versus a placebo for bipolar depression in adults
📍 Noble Clinical Research · Tucson, AZ · +27 more US sites · Get directions →
X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).
- Depression
Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures
Testing how feasible it is to prescribe antidepressants after fragility fractures in adults 50 and
📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →
The goal of this pilot study is to learn about the feasibility about prescribing anti-depressants at discharge in patients aged 50 years and older with a lower extremity fragility fracture. The main questions it aims to answer are: * What are the obstacles to enrolling patients and prescribing anti-depressants among older adults?
- Depression
Dopaminergic Therapy for Anhedonia - 2
Testing an 8-week treatment using L-DOPA for depression with low pleasure and high inflammation
📍 Emory University Hospital · Atlanta, GA · Get directions →
The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks.
- Heart / cardiovascular diseaseKidney disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Testing whether orforglipron changes heart outcomes in adults with heart disease and/or kidney
📍 Instituto de Investigaciones Clínicas Bahia Blanca · Bahía Blanca, · Get directions →
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
- Kidney disease
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
Comparing how two beta-blockers work in hemodialysis patients on heart outcomes
📍 VA Long Beach Healthcare System, Long Beach, CA · Long Beach, CA · +7 more US sites · Get directions →
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
- Kidney disease
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
Testing whether empagliflozin changes kidney filter injury proteins in African American Veterans
📍 Washington DC Veterans Affairs Medical Center (688) · Washington D.C., DC · Get directions →
Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.
- Depression
Identifying and Treating Depression in the Orthopaedic Trauma Population
Testing how orthopedic trauma teams can screen for depression and treat it with medication
📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →
The goal of this trial is to pilot a way for orthopaedic surgeons to safely screen for depression and provide treatment for depression with medication. The main questions it aims to answer are: 1.
- DepressionAnxiety
Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
Studying how gut bacteria in pregnant people relates to depression and anxiety
📍 Sunnybrook Health Science Center · Toronto, Ontario · Get directions →
Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies.
- DepressionAnxiety
Nebulized Ketamine for the Treatment of Major Depressive Disorder
Testing a breathing mist of ketamine to reduce symptoms of major depression
📍 Maimonides Medical Center · Brooklyn, NY · Get directions →
This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
- Depression
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Testing azetukalner against a placebo for major depression in adults
📍 IMA Clinical Research Phoenix · Phoenix, AZ · +39 more US sites · Get directions →
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
- Sickle cell disease
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Testing rilzabrutinib for safety and effectiveness in sickle-cell disease
📍 University of Alabama at Birmingham- Site Number : 8400003 · Birmingham, AL · +15 more US sites · Get directions →
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B).
- Depression
Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine
Testing how ketamine changes brain chemicals in people with depression
📍 University of Pennsylvania · Philadelphia, PA · Get directions →
In the treatment of Major Depressive Disorder (MDD), ketamine can produce rapid but short-lasting improvements in mood. In order to develop a new generation of treatments with rapid and sustained efficacy, a better understanding of the mechanism of action is urgently needed.
- Depression
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Testing a deuterated psilocin-related medicine for major depression
📍 UAB Psychiatry and Behavioral Neurology · Birmingham, AL · +32 more US sites · Get directions →
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/
- DepressionAnxiety
Integrating Inuit Knowledge Principles in Multi-Level Mental Health Clinical Trials
Testing whether eating more country foods and cultural activities help Inuit adults with depression
📍 Aqqiumavvik Society · Arviat, Nunavut · Get directions →
This study is looking at how eating more country foods affects mental health among Inuit men and women in Arviat, NU. The goal is to evaluate if eating more of these foods helps people feel less depressed or anxious, and whether being part of food-gathering and cultural activities also makes a difference.
- Kidney disease💵 May compensate
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease
Testing kidney disease drug effects and safety in teens with early CKD
📍 Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →
Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.
- Depression
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Testing brenipatide to see if it delays return of major depression symptoms
📍 Accellacare - Moorpark · Moorpark, CA · +31 more US sites · Get directions →
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a treatment period that will last a minimum of 12 months, and the follow up period that will last approximately 2 months.
- DepressionAnxiety
Creatine for Depressed Male and Female Methamphetamine Users
Testing whether creatine helps depression and anxiety in people who use meth
📍 Montana State University College of Nursing (Missoula campus) · Missoula, MT · Get directions →
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression
- Kidney disease
Randomised Evaluation of Sodium Dialysate Levels on Vascular Events
Testing whether two dialysate salt levels affect heart events and death
📍 Royal Adelaide Hospital · Adelaide, · Get directions →
This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.
- Kidney disease
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Testing etelcalcetide in children with kidney disease on dialysis
📍 Childrens Hospital of Los Angeles · Los Angeles, CA · +9 more US sites · Get directions →
This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
- Type 2 diabetesKidney disease💵 May compensate
Mechanism of SGLT2 Inhibition in the Kidney
Testing how SGLT2 medicines affect kidney function in type 2 diabetes
📍 University of Michigan · Ann Arbor, MI · Get directions →
The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.
- Kidney disease
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
Testing medicines before surgery to reduce bleeding in kidney patients
📍 London Health Sciences Centre · London, Ontario · Get directions →
The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.
- Depression
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
Comparing best step-by-step treatments for depression with anxiety
📍 University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience · Cincinnati, OH · Get directions →
Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.
- Depression
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Testing an experimental medicine against a placebo for depression
📍 Lighthouse Psychiatry · Gilbert, AZ · +26 more US sites · Get directions →
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend
- Kidney disease
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Testing long-term safety and effectiveness of zigakibart in adults with IgA kidney disease
📍 Colorado Kidney Care Nephrology · Denver, CO · +6 more US sites · Get directions →
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.
- Depression
Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth
Testing how NAC and MBCT affect brain chemistry linked to depression in teens
📍 University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience · Cincinnati, OH · Get directions →
The primary goal is to investigate to what extent changes in glutamate and glutathione modulation and functional integration between brain networks associated with emotion and attention regulation are associated with treatment response in mildly depressed youth.
- Kidney disease
Concomitant Renal and Urinary Bladder Allograft Transplantation
Testing whether transplanting a new kidney and bladder at the same time is possible for people with
📍 Mayo Clinic · Rochester, MN · +1 more US site · Get directions →
The purpose of this study is to establish if concomitant renal and vascularized urinary bladder allograft transplantation is feasible.
- Depression
Probiotic Administration for Adolescent Depression
Testing whether a probiotic affects brain and gut in teens with depression
📍 UCSF · San Francisco, CA · Get directions →
This double-blind, placebo-controlled clinical trial will examine the effect of probiotic Visbiome on the brain and gut microbiome of individuals 15 to 24 years of age.
- Depression
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Testing how one dose of psilocybin affects self-focused thinking in depression
📍 Athinoula A. Martinos Center for Biomedical Imaging · Charlestown, MA · Get directions →
This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.
- Depression
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Testing how well a medicine works to treat depression with daytime sleepiness
📍 Clinical Research Site · Chino, CA · +12 more US sites · Get directions →
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.
- Depression
Neural Circuit Effects of Ketamine in Depression
Testing how ketamine affects brain activity and depression symptoms
📍 Icahn School of Medicine at Mount Sinai · New York, NY · Get directions →
This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.
- Kidney disease
Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
Testing whether a trial of SGLT2 inhibitors in youth with chronic kidney disease is feasible
📍 Ann & Robert H. Lurie Children's Hospital of Chicago · Chicago, IL · Get directions →
The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease.
- Heart / cardiovascular diseaseKidney disease💵 May compensate
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Testing whether sotagliflozin can slow kidney damage in type 1 diabetes
📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.
- Depression
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Comparing a drug called AXS-05 with bupropion to prevent depression relapse
📍 Clinical Research Site · Bellflower, CA · +39 more US sites · Get directions →
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
- Depression
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Testing whether adding NBI-1065845 helps prevent relapse of depression
📍 Neurocrine Clinical Site · Oceanside, CA · +17 more US sites · Get directions →
The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.
- Depression
A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
Testing a brain stimulation treatment to help knee arthritis pain and depression
📍 UCLA Semel Institute - Neuropsychiatric Institute (NPI) · Los Angeles, CA · Get directions →
Osteoarthritis (OA) is a major public health problem, and involvement of the knee is especially disabling. Symptomatic knee OA has an incidence rate between 40 to 1,020 per 100,000 person years1 and is among the most common causes of disability worldwide.
- Depression
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Testing whether adding NBI-1065845 helps improve depression symptoms
📍 Neurocrine Clinical Site · Huntsville, AL · +9 more US sites · Get directions →
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Kidney disease
Bone in CKD Alkali Response (BICARb Pilot Trial)
Testing whether potassium citrate improves bone health in people with chronic kidney disease
📍 Albert Einstein College of Medicine · The Bronx, NY · +1 more US site · Get directions →
The goal of this clinical trial is to test whether potassium citrate improves skeletal health in adults and children with chronic kidney disease. The main questions it aims to answer are: * To evaluate effects of potassium citrate treatment on bone quality and strength.
- DepressionDementia / Alzheimer's
Aβ Dynamics in LLMD
Testing how treating depression may change brain markers linked to Alzheimer’s
📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →
This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers.
- Depression
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Testing a biomarker prediction tool to forecast depression treatment outcomes
📍 University of Calgary · Calgary, Alberta · Get directions →
This is a study that will test a predictive biomarker algorithm based on results from a previous study. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).
- Type 2 diabetesKidney disease
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
Testing whether people with type 2 diabetes have early hormone-related kidney risk
📍 Brigham and Women's Hospital · Boston, MA · Get directions →
The aim of this protocol is to assess the presence and severity of primary aldosteronism pathophysiology in patients with type 2 diabetes who have, or are at-risk for developing, chronic kidney disease.
- Depression
Confirmatory Efficacy Trial of Attention Bias Modification for Depression
Testing two types of attention-bias training for adults with depression
📍 Institute for Mental Health Research · Austin, TX · Get directions →
The goal of this clinical trial is to compare the efficacy of two related, but different ABM (Attention Biased Modification) treatments for depression in adults with elevated symptoms of depression. The main aims are: * Aim 1:examine whether gamified ABM leads to greater change in the primary and secondary outcomes than sham ABM * Aim 1: establish that gamified ABM is at least as effective as traditional ABM.
- Sickle cell disease
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
Testing whether routine red blood cell transfusions in pregnancy reduce sickle cell flare-ups or
📍 Grady Health System · Atlanta, GA · Get directions →
The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-related complications requiring acute health care encounters (acute care/ER/Hospital visits) or resulting in death over the entirety of pregnancy until 2 months post-partum in women with SCD. RBC transfusion is the only disease-modifying therapy for pregnant women with SCD, and it is considered a standard treatment option however, there exists no consensus on the role of transfusion therapy in preventing SCD-related pregnancy complications.
- Depression
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Testing whether esketamine added to standard care reduces depression symptoms in teens with recent
📍 University of Alabama at Birmingham · Birmingham, AL · +5 more US sites · Get directions →
The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder characterized by a persistent feeling of sadness and loss of interest in activities) as compared with psychoactive placebo (does not contain JNJ-54135419) plus SoC in adolescent participants with acute suicidal ideation or behavior.
- Depression
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Testing an add-on treatment to see if it helps people with major depression symptoms
📍 Neurocrine Clinical Site · Chino, CA · +14 more US sites · Get directions →
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Depression
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Testing the long-term safety of an added treatment for major depression
📍 Neurocrine Clinical Site · Huntsville, AL · +39 more US sites · Get directions →
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
- Sickle cell disease
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
Testing a single pneumococcal vaccine dose in children with sickle cell disease
📍 Site # 8400006 · Atlanta, GA · +4 more US sites · Get directions →
The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.
- DepressionAnxiety
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
Testing a cognitive training program to see brain and thinking changes in people with depression or
📍 UC San Diego · San Diego, CA · Get directions →
The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to one of two groups.
- Kidney disease
SAfety of Regional Citrate Anticoagulation (SARCA Study)
Testing the safety of regional citrate blood-thinner use in adults
📍 John L. McClellan Memorial Veterans' Hospital · Little Rock, AR · +9 more US sites · Get directions →
This is an Open-label, Prospective, Multicenter Study to Assess the SAfety of Regional Citrate Anticoagulation Delivered by the multiFiltratePRO system in Adult Patients Requiring Continuous Renal Replacement Therapy (SARCA Study).
- Depression
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Testing a low-amplitude seizure treatment vs standard ECT for suicidal thoughts in depression
📍 Pine Rest Christian Mental Health Services · Grand Rapids, MI · Get directions →
This protocol proposes an initial randomized clinical trial that includes all patients with suicidal ideation (SI) at baseline, and with SI as the primary outcome measure to examine whether Right Unilateral Low-Amplitude Pulse - Seizure Therapy (RUL LAP-ST) treatment has more magnitude and rate of remission of SI as conventional pulse amplitude Right Unilateral Electroconvulsive Therapy (RUL ECT) (based on our prior secondary analysis). Our central hypothesis is that RUL LAP-ST has significantly less cognitive/memory side effects (no memory side effects were noted in our prior studies for 500mA and 600mA) and thus is more favorable in terms of side effects compared to RUL conventional pulse amplitude ECT, while maintaining better anti-suicidal effect.
- Depression
Low Frequency Right Dorsolateral Pre Frontal Cortical Repetitive TMS for Bipolar Depression
Testing low-frequency repetitive brain stimulation for bipolar depression
📍 University Health Network Toronto Western Hospital · Toronto, Ontario · Get directions →
The purpose of this trial is to conduct an adequately powered clinical trial of once daily LFR for individuals diagnosed with treatment-resistant BD-DE who have not responded to iTBS or sham treatment applied to the left DLPFC. This work will develop the evidence supporting the use of LFR rTMS for individuals with treatment-resistant BD-DE who currently have limited treatment options to alleviate their suffering.
- Kidney disease
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Testing a treatment for adults with chronic kidney disease to help slow progression
📍 Apogee Clinical Research · Huntsville, AL · +39 more US sites · Get directions →
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study.
- Depression
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Testing whether adding seltorexant to antidepressants helps depression and sleep in adults with
📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →
The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
- Depression
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Testing whether adding milsaperidone helps people with depression, and checking side effects
📍 Vanda Investigational Site · Phoenix, AZ · +20 more US sites · Get directions →
The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder
- Depression
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Testing a depression add-on treatment in people with major depression
📍 Scottsdale Research Institute · Phoenix, AZ · +38 more US sites · Get directions →
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
- Showing the first 60 of 115. Add filters or a location to narrow down.